Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial

Anthony B. El-Khoueiry, Bruno Sangro, Thomas Yau, +18

The Lancet

HepatologyMedicineExpansion TrialLiver CancerAdvanced Hepatocellular Carcinoma +7

Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study

Marina Chiara Garassino, Byoung Chul Cho, Joo-Hang Kim, +148

The Lancet Oncology

MedicineImmunologyPathologyImmune Checkpoint InhibitorCancer Treatment +3

Antitumor Activity of Nivolumab in Recurrent and Metastatic Nasopharyngeal Carcinoma: An International, Multicenter Study of the Mayo Clinic Phase 2 Consortium (NCI-9742)

Wan‐Teck Lim, Boon Cher Goh, Edwin P. Hui, +21

Journal of Clinical Oncology

Metastatic NpcOncologyAntitumor ActivityPd-l1 ExpressionMedicine +13

Nivolumab in advanced hepatocellular carcinoma: Sorafenib-experienced Asian cohort analysis

Thomas Yau, Chiun Hsu, Tae‐You Kim, +14

Journal of Hepatology

Phase I/II safety and antitumor activity of nivolumab in patients with advanced hepatocellular carcinoma (HCC): CA209-040.

Anthony B. El-Khoueiry, Ignacio Melero, Todd S. Crocenzi, +9

Journal of Clinical Oncology

Antitumor ActivityImmunologyPharmacotherapyImmunotherapeuticsImmunotherapy +18

Nivolumab (nivo) in sorafenib (sor)-naive and -experienced pts with advanced hepatocellular carcinoma (HCC): CheckMate 040 study.

Todd S. Crocenzi, Anthony B. El-Khoueiry, Thomas Cheung Yau, +16

Journal of Clinical Oncology

ImmunologyPathologyPharmacotherapyImmunotherapeuticsImmunotherapy +19

Impact of antitumor activity on survival outcomes, and nonconventional benefit, with nivolumab (NIVO) in patients with advanced hepatocellular carcinoma (aHCC): Subanalyses of CheckMate-040.

Anthony B. El-Khoueiry, Ignacio Melero, Thomas Cheung Yau, +14

Journal of Clinical Oncology

Antitumor ActivitySor-exp PtsPathologyImmunotherapeuticsPharmacotherapy +19

Nivolumab in sorafenib-naive and sorafenib-experienced patients with advanced hepatocellular carcinoma: 5-year follow-up from CheckMate 040

Anthony B. El-Khoueiry, Jörg Trojan, Tim Meyer, +15

Annals of Oncology

Non-invasive detection of actionable mutations in advanced non-small-cell lung cancer using targeted sequencing of circulating tumor DNA

Wey Cheng Sim, Chet Hong Loh, Grace Li-Xian Toh, +4

Lung Cancer

SequencingHealth SciencesSomatic VariantTumor HeterogeneityMedicine +10

Phase I/II safety and antitumor activity of nivolumab in patients with advanced hepatocellular carcinoma (HCC): CA209-040.

Anthony B. El-Khoueiry, Ignacio Melero, Todd S. Crocenzi, +9

Journal of Clinical Oncology

Antitumor ActivityCancer ManagementPathologyCancer Cell BiologyClinical Oncology +16